Titan Partners analyst Boris Peaker initiated coverage of Genelux (GNLX) with a Buy rating and $20 price target The development-stage biotechnology company has an oncolytic viral therapy in a pivotal Phase 3 study, OnPrime, in ovarian cancer with data anticipated in the first half of 2026, notes the analyst, who says the firm’s 12-18 month price target assumes positive results from OnPrime. Updates from ongoing studies in NSCLC and SCLC by year-end can act as additional catalysts, but are not factored into the firm’s valuation, the analyst added.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GNLX:
- Genelux Corp.’s OnPrime Study: A Potential Game-Changer in Ovarian Cancer Treatment
- Genelux Corp. Advances Phase 2 Study in NSCLC with Promising New Treatment
- Genelux Corp: Strong Buy Rating Backed by Promising Olvi-Vec Developments and Sector Momentum
- Genelux price target raised to $20 from $10 at Maxim
- Genelux initiated with a Buy at Lake Street